The addition of GCGR agonism to GLP-1R agonism may therefore prove to be more efficacious in the treatment of type 2 diabetes and obesity, producing additive effects on energy intake and expenditure. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.